341
80. Alexandrov K, Rojas M, Satarug S. The critical DNA damage by benzo (a) pyrene in lung tissues of smokers and approaches to preventing its formation. Toxicol Lett. 2010;198(1):63–8.
81. Miller KP, Ramos KS. Impact of cellular metabolism on the biological effects of benzo [a]
pyrene and related hydrocarbons. Drug Metab Rev. 2001;33(1):1–35.
82. Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within
the vascular wall: implications for human atherogenesis. Drug Metab Rev. 2005;37(4):595–610.
83. Rybicki BA, Nock NL, Savera AT, Tang D, Rundle A. Polycyclic aromatic hydrocarbon-DNA
adduct formation in prostate carcinogenesis. Cancer Lett. 2006;239(2):157–67.
84. Liu Y, Vinje J, Pacifico C, Natile G, Sletten E. Formation of adenine− n3/guanine− n7 crosslink in the reaction of trans-oriented platinum substrates with dinucleotides. J Am Chem Soc.
2002;124(43):12854–62.
85. Yang P, Ma J, Zhang B, Duan H, He Z, Zeng J, et al. CpG site–specific hypermethylation
of p16INK4α in peripheral blood lymphocytes of PAH-exposed workers. Cancer Epidemiol
Biomark Prev. 2012;21(1):182–90.
86. Berge G, Mollerup S, Øvrebø S, Hewer A, Phillips DH, Eilertsen E, et al. Role of estrogen
receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung
Cancer. 2004;45(3):289–97.
87. Käfferlein HU, Marczynski B, Mensing T, Brüning T. Albumin and hemoglobin adducts of
benzo [a] pyrene in humans—analytical methods, exposure assessment, and recommendations
for future directions. Crit Rev Toxicol. 2010;40(2):126–50.
88. Kwack SJ, Mu LB. Correlation between DNA or protein adducts and benzo [a] pyrene diol
epoxide I–triglyceride adduct detected in vitro and in vivo. Carcinogenesis. 2000;21(4):629–32.
89. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutation
research/environmental mutagenesis and related subjects, Amsterdam:Elsevier.
1983;113(3–4):173–215
90. Olajire AA, Altenburger R, Küster E, Brack W. Chemical and ecotoxicological assessment
of polycyclic aromatic hydrocarbon—contaminated sediments of the Niger Delta, Southern
Nigeria. Sci Total Environ. 2005;340(1–3):123–36.
91. Matson CW, Gillespie AM, McCarthy C, McDonald TJ, Bickham JW, Sullivan R, et al. Wildlife
toxicology: biomarkers of genotoxic exposures at a hazardous waste site. Ecotoxicology.
2009;18(7):886–98.
92. Harman C, Farmen E, Tollefsen KE. Monitoring North Sea oil production discharges using
passive sampling devices coupled with in vitro bioassay techniques. J Environ Monit.
2010;12(9):1699–708.
93. Mackay D, Shiu WY. Aqueous solubility of polynuclear aromatic hydrocarbons. J Chem Eng
Data. 1977;22(4):399–402.
94. Howard P, Meylan W, Aronson D, Stiteler W, Tunkel J, Comber M, et al. A new biodegradation prediction model specific to petroleum hydrocarbons. Environ Toxicol Chem Int
J. 2005;24(8):1847–60.
95. Comber M, Den Haan K, Djemel N, Eadsforth C., King D. Paumen ML, et al. Primary biodegradation of petroleum hydrocarbons in seawater. Concawe report 10/12; 2012.
19 Role of Polycyclic Aromatic Hydrocarbons as EDCs in Metabolic Disorders
80. Alexandrov K, Rojas M, Satarug S. The critical DNA damage by benzo (a) pyrene in lung tissues of smokers and approaches to preventing its formation. Toxicol Lett. 2010;198(1):63–8.
81. Miller KP, Ramos KS. Impact of cellular metabolism on the biological effects of benzo [a]
pyrene and related hydrocarbons. Drug Metab Rev. 2001;33(1):1–35.
82. Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within
the vascular wall: implications for human atherogenesis. Drug Metab Rev. 2005;37(4):595–610.
83. Rybicki BA, Nock NL, Savera AT, Tang D, Rundle A. Polycyclic aromatic hydrocarbon-DNA
adduct formation in prostate carcinogenesis. Cancer Lett. 2006;239(2):157–67.
84. Liu Y, Vinje J, Pacifico C, Natile G, Sletten E. Formation of adenine− n3/guanine− n7 crosslink in the reaction of trans-oriented platinum substrates with dinucleotides. J Am Chem Soc.
2002;124(43):12854–62.
85. Yang P, Ma J, Zhang B, Duan H, He Z, Zeng J, et al. CpG site–specific hypermethylation
of p16INK4α in peripheral blood lymphocytes of PAH-exposed workers. Cancer Epidemiol
Biomark Prev. 2012;21(1):182–90.
86. Berge G, Mollerup S, Øvrebø S, Hewer A, Phillips DH, Eilertsen E, et al. Role of estrogen
receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung
Cancer. 2004;45(3):289–97.
87. Käfferlein HU, Marczynski B, Mensing T, Brüning T. Albumin and hemoglobin adducts of
benzo [a] pyrene in humans—analytical methods, exposure assessment, and recommendations
for future directions. Crit Rev Toxicol. 2010;40(2):126–50.
88. Kwack SJ, Mu LB. Correlation between DNA or protein adducts and benzo [a] pyrene diol
epoxide I–triglyceride adduct detected in vitro and in vivo. Carcinogenesis. 2000;21(4):629–32.
89. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutation
research/environmental mutagenesis and related subjects, Amsterdam:Elsevier.
1983;113(3–4):173–215
90. Olajire AA, Altenburger R, Küster E, Brack W. Chemical and ecotoxicological assessment
of polycyclic aromatic hydrocarbon—contaminated sediments of the Niger Delta, Southern
Nigeria. Sci Total Environ. 2005;340(1–3):123–36.
91. Matson CW, Gillespie AM, McCarthy C, McDonald TJ, Bickham JW, Sullivan R, et al. Wildlife
toxicology: biomarkers of genotoxic exposures at a hazardous waste site. Ecotoxicology.
2009;18(7):886–98.
92. Harman C, Farmen E, Tollefsen KE. Monitoring North Sea oil production discharges using
passive sampling devices coupled with in vitro bioassay techniques. J Environ Monit.
2010;12(9):1699–708.
93. Mackay D, Shiu WY. Aqueous solubility of polynuclear aromatic hydrocarbons. J Chem Eng
Data. 1977;22(4):399–402.
94. Howard P, Meylan W, Aronson D, Stiteler W, Tunkel J, Comber M, et al. A new biodegradation prediction model specific to petroleum hydrocarbons. Environ Toxicol Chem Int
J. 2005;24(8):1847–60.
95. Comber M, Den Haan K, Djemel N, Eadsforth C., King D. Paumen ML, et al. Primary biodegradation of petroleum hydrocarbons in seawater. Concawe report 10/12; 2012.
19 Role of Polycyclic Aromatic Hydrocarbons as EDCs in Metabolic Disorders